Portfolio Update

RNS Number : 6144R

Intl. Biotechnology Trust PLC

12 December 2016

 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)

Portfolio Update as at 30 November 2016

Net Assets	£229m
Net Assets per share	609p
Share price	559p
Total value of unquoted investments	£26m
Total number of portfolio companies	79

Top Ten Holdings

Company Name	% NAV
Celgene	7.5
Biogen	6.8
Genmab	6.4
Alexion	5.8
Actelion	5.0
Gilead	4.5
Tesaro	4.5
Shire	4.5
Regeneron	4.3
Ariad	3.1
	-----------
Total	52.4

Geographical Allocation	% NAV
US & Canada	74
Europe & UK	26
	-----------
Total	100

Quoted/Unquoted Allocation	% NAV
Quoted	89
Unquoted	11
	-----------
Total	100

NAV % Market Cap	% NAV
Large Cap >USD10BN	59
Mid Cap =USD1-10BN	20
Small Cap <USD1BN	21
	-----------
Total	100

NAV % by Therapeutic Areas	% NAV
Oncology	35
Orphan	18
Inflammation	8
Ophthalmology	5
CNS	9
Medtech	3
Other	22
	-----------
Total	100

Unquoted portfolio update

The Board notes the following changes in valuation to the unquoted portfolio during November 2016:

Due to a recapitalisation of NCP Holdings, the Company received proceeds of £1.2m in exchange for 47.5% of our holding. The value of the remaining holding has reduced from £2.1m to £1.7m and the net impact on the NAV was an increase of £0.8m. The sale of Atopix was finalised and we received proceeds of £0.5m on completion of the sale to Chiesi Farmaceutici. This led to an overall increase of £0.1m to NAV reflecting both the cash received and the value of future milestone payments which may be received. A milestone was received from Biogen in relation to Convergence Pharmaceuticals totalling £0.6m, an increase to the valuation of £0.1m. The valuation of Cell Medica Limited increased by £0.1m due to an increase in the expected receipt of milestones related to the sale of Delenex dermatology assets. A £0.3m increase in value of an unquoted company which cannot be named due to sensitive business development discussions which are on-going. A range of likely business development outcomes are being discussed with a further positive valuation impact of between £1.0m and £2.3m, which due to the uncertainty of the discussions have not been included in the current NAV.

The net impact of these changes to the NAV was an increase of £1.4m or 3.46p per share.

In addition, we note the reverse merger of Kalvista Pharmaceuticals with Carbylan completed on 22 November 2016. This investment is now listed on the Nasdaq stock exchange.

BNP Paribas Secretarial Services Limited

Company Secretary

12 DECEMBER 2016

 

END

 

 

PFUBLBDDIGBBGLD